Clinical Trials
13 trialsNCT06120140 2026-05-08
COCOON
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT02274662 2025-01-16
Expanded Access Protocol Thymus Transplantation
Sumitomo Pharma Switzerland GmbH
Phase 4 Completed
NCT02663622 2024-01-23
MK-7110-002
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Completed
NCT04095858 2023-02-08
CATHY
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT00136903 2022-01-31
Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)
Mesoblast, Ltd.
Phase 2 Completed
NCT01325571 2016-03-09
A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis
Astellas Pharma Inc
Phase 3 Completed
NCT00309088 2014-08-25
FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients
Astellas Pharma Inc
Phase 3 Completed
NCT01745159 2014-08-05
Preventive Treatment of Tacrolimus Ointment in Children With Atopic Dermatitis
Astellas Pharma Inc
Phase 4 Completed
NCT01983761 2013-11-18
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
Targazyme, Inc.
Phase 1/2 Unknown
NCT00890500 2013-10-08
Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.
Fate Therapeutics
Phase 1 Completed
NCT00129961 2012-04-11
Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 4 Completed
NCT00106392 2010-11-23
A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
Astellas Pharma Inc
Phase 4 Completed
NCT00309101 2009-06-03
An Open Study for Steroid Resistant, Non-Thymectomized MG Patients
Astellas Pharma Inc
Phase 3 Completed